Invokamet FDA Approval History
FDA Approved: Yes (First approved August 8, 2014)
Brand name: Invokamet
Generic name: canagliflozin and metformin
Dosage form: Tablets
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Diabetes, Type 2, Cardiovascular Risk Reduction
Invokamet (canagliflozin/metformin) is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination indicated for the treatment of type 2 diabetes, and to reduce the risk of cardiovascular events (including heart attack, stroke or death) in adults with type 2 diabetes and established cardiovascular disease.
Development Timeline for Invokamet
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.